STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
Study Details
Study Description
Brief Summary
This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have been treated. STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system's response to STEMVAC.
Detailed Description
OUTLINE:
Patients receive STEMVAC vaccine with sargramostim intradermally (ID) every month for 3 months in the absence of disease progression or unacceptable toxicity. Patients then receive STEMVAC vaccine with sargramostim ID booster injections 3 months after the 3rd vaccination and 6 months after the 1st booster vaccination.
After completion of study treatment, patients are followed up at 28 days, and then annually for 5 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Prevention (STEMVAC vaccine, sargramostim) Patients receive STEMVAC vaccine with sargramostim ID every month for 3 months in the absence of disease progression or unacceptable toxicity. Patients then receive STEMVAC vaccine with sargramostim ID booster injections 3 months after the 3rd vaccination and 6 months after the 1st booster vaccination. |
Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Given IV
Other Names:
Biological: Sargramostim
Given ID
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Cellular immune response: incidence [At 1 month after 3rd vaccination]
Defined by the incidence of development of the Th1 (IFN-gamma [g]) antigen specific immune response against STEMVAC antigens using enzyme-linked immunosorbent spot assay (ELISPOT).
- Cellular immune response: incidence [At 10 months after 3rd vaccination]
Defined by the incidence of development of the Th1 (IFN-gamma [g]) antigen specific immune response against STEMVAC antigens using enzyme-linked immunosorbent spot assay (ELISPOT).
- Cellular immune response: magnitude [At 1 month after 3rd vaccination]
Defined by the magnitude of development of the Th1 (IFN-gamma [g]) antigen specific immune response against STEMVAC antigens using enzyme-linked immunosorbent spot assay (ELISPOT). The magnitude of immune response is defined as the sum of the corrected spots/well values calculated at each time point.
- Cellular immune response: magnitude [At 3 months after 3rd vaccination]
Defined by the magnitude of development of the Th1 (IFN-gamma [g]) antigen specific immune response against STEMVAC antigens using enzyme-linked immunosorbent spot assay (ELISPOT). The magnitude of immune response is defined as the sum of the corrected spots/well values calculated at each time point.
- Cellular immune response: magnitude [At 9 months after 3rd vaccination]
Defined by the magnitude of development of the Th1 (IFN-gamma [g]) antigen specific immune response against STEMVAC antigens using enzyme-linked immunosorbent spot assay (ELISPOT). The magnitude of immune response is defined as the sum of the corrected spots/well values calculated at each time point.
- Cellular immune response: magnitude [At 10 months after 3rd vaccination]
Defined by the magnitude of development of the Th1 (IFN-gamma [g]) antigen specific immune response against STEMVAC antigens using enzyme-linked immunosorbent spot assay (ELISPOT). The magnitude of immune response is defined as the sum of the corrected spots/well values calculated at each time point.
Secondary Outcome Measures
- Kinetics of the magnitude of antigen specific IFN-gamma ELISPOT counts [13 months]
Will be assessed over time from pre to post immunization to determine if pre-existent immunity affects magnitude of response.
- Incidence of adverse events [1 month after last booster vaccine]
Safety and systemic toxicity will be determined by chemical and clinical parameters evaluated at various time points. Toxicity grading will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events will be done per Food and Drug Administration and NCI guidelines.
- Activation status and repertoire diversity of peripheral blood T-cells [Prior to and after STEMVAC vaccination]
The peripheral T cell repertoire diversity will be determined by high-throughput deoxyribonucleic acid (DNA) sequencing of the recombined V(D)J region of the T cell receptor beta-chain (TCRB) using the immunoSEQ platform (Adaptive Biotechnologies) on antigen-specific T-cells from a short-term in vitro culture. The activation, exhaustion and memory status of the peripheral T cells will be determined by flow cytometry using fluorochrome linked antibodies to PD-1, CD4, CD3, LAG3, CD137, CD8, KLGR1, CD44, CD69, CD62L and OX40. Transcription factors for Th1 (Tbet), Th2 (GATA3) and Treg (FOXP3) will also be evaluated. All results will be summarized using simple descriptive statistics.
- Relapse free survival (RFS) [Up to 5 years]
Will explore if adjuvant vaccination with STEMVAC improves relapse free survival as compared to historical controls. Local and distant recurrence at year 5 will be reported as proportion with confidence intervals, and RFS will be estimated using Kaplan-Meier method with the 5-year RFS rate estimated from the Kaplan-Meier estimate of the survival distribution along with a 95% confidence interval. Comparison of the local and distant recurrence and 5-year RFS against the historical control will be based on a binomial test.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants with triple negative breast cancer, stages IB, II or III. Estrogen receptor (ER)-negative and progesterone receptor (PR)-negative is defined as breast cancer with less than 1% of ER or PR expression. HER2 negative is defined as:
-
0-1+ HER2 expression by immunohistochemistry (IHC) OR
-
Fluorescence in situ hybridization (FISH) negative OR
-
HER2 2+ and FISH negative
-
Participants must have completed standard of care systemic therapy (including immune modulating agents) and radiotherapy if used between 28 and 365 days prior to enrollment
- Note: Treatment with a bisphosphonate or denosumab to prevent bone loss is not considered to be systemic therapy for breast cancer and its use within the 28 day pre-enrollment period or while on study is not exclusionary
-
Participants must agree to avoid systemic steroids for the duration of the treatment period and until completion of the 1 month post 2nd booster vaccine visit (end of treatment)
-
Participants must be at least 18 years of age
-
Participants must have Eastern Cooperative Oncology Group (ECOG) performance status score of =< 1
-
White blood cell (WBC) >= 3000/mm^3 (within 60 days of enrollment and at least 28 days post standard of care [SOC] treatment)
-
Lymphocyte count >= 800/mm^3 (within 60 days of enrollment and at least 28 days post standard of care [SOC] treatment)
-
Platelet count >= 100,000/mm^3 (within 60 days of enrollment and at least 28 days post standard of care [SOC] treatment)
-
Hemoglobin (Hgb) >= 10 mg/dl (within 60 days of enrollment and at least 28 days post standard of care [SOC] treatment)
-
Serum creatinine =< 1.2 mg/dl OR creatinine clearance > 60 ml/min (within 60 days of enrollment and at least 28 days post standard of care [SOC] treatment)
-
Total bilirubin =< 1.5 X upper limit of institutional normal (ULN) (within 60 days of enrollment and at least 28 days post standard of care [SOC] treatment)
-
AST (aspartate aminotransferase)/serum glutamic-oxaloacetic transaminase (SGOT) =< 1.5 X upper limit of institutional normal (ULN) (within 60 days of enrollment and at least 28 days post standard of care [SOC] treatment)
-
Must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
-
The effects of STEMVAC on the developing human fetus are unknown. For this reason,
-
Female participant agrees to use adequate contraception (examples include: estrogen and/or progestogen containing hormonal contraception, barrier method (condom, cervical cap) or abstinence) while on the study and until 1 month after the 2nd booster vaccination when/if engaging in sex that could lead to pregnancy. Exceptions: Females who have had a hysterectomy, tubal ligation or bilateral oophorectomy OR meet one of the following criteria for postmenopausal: Age > 60 or age < 60 with >= 12 months amenorrhea and follicle-stimulating hormone (FSH) within the testing facility's postmenopausal range
-
Female participant agrees to inform her study physician immediately should she become pregnant or suspect she is pregnant while participating in this study
-
Male participants who are having sex that can lead to pregnancy must use an acceptable form of contraception (vasectomy with the absence of sperm, sexual abstinence, condoms) throughout the course of the study
-
Patients must be willing to not undergo major elective surgical procedures with general anesthesia or conscious sedation through the end of treatment visit. (Note: port removal is allowable)
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Contraindication or known hypersensitivity to receiving sargramostim (rhuGM-CSF) or other yeast based products
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to STEMVAC
-
Participants receiving any other investigational agents or enrolled in any other treatment study
-
Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) is prohibited during the treatment period of the study, except when taken as low-dose (81 mg) aspirin therapy. Prohibited chronic use is defined as daily use for more than 7 days
-
Participants with any clinically significant autoimmune disease uncontrolled with treatment
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnant and breastfeeding women are excluded from this study
-
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
- Note: These individuals are excluded in order to avoid confounding an existing condition with an immune response to STEMVAC
- Has > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 (mild) residual toxicity from prior breast cancer treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | United States | 98109 |
| 2 | University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | United States | 53792 |
Sponsors and Collaborators
- University of Washington
- National Cancer Institute (NCI)
- University of Wisconsin, Madison
Investigators
- Principal Investigator: Mary Disis, MD, Fred Hutch/University of Washington Cancer Consortium
- Study Director: Howard Bailey, MD, University of Wisconsin, Madison
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RG1122380
- NCI-2021-07734
- UG1CA242635
- UWI20-00-01